(Cervical Cancer) Libtayo (Cemiplimab) Launched in Japan for Recurrent/Progressive Disease

• March 30, 2023
• 1 min read

On March 30, 2023, Sanofi Japan announced the commercial launch of Libtayo (cemiplimab) IV infusion, an anti-PD-1 antibody drug, for the treatment of cervical cancer that has progressed or recurred following chemotherapy.

Cervical cancer is most commonly caused by HPV infection. Approximately 80% of cases are squamous cell carcinoma, with the remainder being primarily adenocarcinoma. Treatment options are limited for patients with progressive or recurrent disease.

This approval is based on the EMPOWER-Cervical 1 Phase 3 clinical trial, an international multicenter study enrolling patients (N=608) with recurrent or metastatic cervical cancer. Patients were randomized to receive Libtayo (350 mg every 3 weeks as second-line therapy, N=304) or investigator's choice of chemotherapy (N=304). The primary endpoints were overall survival (OS) and progression-free survival (PFS).

Key Results:

• Median OS: Libtayo 12.0 months vs. chemotherapy 8.5 months — statistically significant improvement

Sanofi Japan stated that the company will continue to collaborate with co-developer Regeneron to bring hope to cervical cancer patients in Japan, and to further contribute to patients, families, and healthcare providers.

Source: https://www.sanofi.co.jp/dam/jcr:0a6fdb34-9135-4f48-9c4a-ff178bcb58fc/230330.pdf

Cervical Cancer | Immunotherapy | Libtayo | Cemiplimab

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4